Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2021 Nov 18;12:789192. doi: 10.3389/fphar.2021.789192

Corrigendum: ErHuang Formula Improves Renal Fibrosis in Diabetic Nephropathy Rats by Inhibiting CXCL6/JAK/STAT3 Signaling Pathway

Yu-Li Shen 1,2,, Yi-ping Jiang 3,, Xiao-Qin Li 1,4,, Su-Juan Wang 5, Ming-Hua Ma 6, Chun-Yan Zhang 7, Jian-Yong Zhu 7, Khalid Rahman 8, Li-Jun Zhang 1,*, Xin Luan 1,2,*, Hong Zhang 1,*
PMCID: PMC8637534  PMID: 34867422

In the original article, there was a mistake during production in Figure 4 as published. Figure 4 is identical to Figure 3. The corrected Figure 4 appears below.

FIGURE 4.

FIGURE 4

EHF inhibited the proliferation of NRK-49F cells and decreased the expression of CXCL6 and CXCR1. (A) CCK8 analysis of NRK-49F cell proliferation. (B), (D) The mRNA and protein expressions of CXCL6 and CXCR1 in different EHF dose groups were examined by qRT-PCR and Western blotting. GAPDH was served as a loading control. (C), (E) The effect of 0.5 mg/ml EHF on the expression of CXCL6 and CXCR1 in CXCL6 overexpression NRK-49F cells was evaluated by qRT-PCR and Western blotting. *p < 0.05, **p < 0.01, ***p < 0.001 versus control group.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES